Baird lowered the firm’s price target on Enanta to $26 from $40 and keeps an Outperform rating on the shares. The firm said results largely met expectations, and we are encouraged that management continues to expect to readout data from the RSVPEDs study of zelicapavir in 3Q24, which Baird continues to view as a key catalyst with potential to drive upside potential on the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENTA: